{
    "title": "114_hr2396",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Sensible Oversight for Technology \nwhich Advances Regulatory Efficiency Act'' or the ``SOFTWARE Act''.\n\nSEC. 2. HEALTH SOFTWARE.\n\n    Section 201 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. \n321) is amended by adding at the end the following:\n    ``(ss)(1) The term `health software' means software that does not, \nthrough use of an in vitro diagnostic device or signal acquisition \nsystem, acquire, process, or analyze an image or physiological signal, \nis not an accessory, is not an integral part of a device necessary to \nsupport the use of the device, is not used in the manufacture and \ntransfusion of blood and blood components to assist in the prevention \nof disease in humans, and--\n                    ``(A) is intended for use for administrative or \n                operational support or the processing and maintenance \n                of financial records;\n                    ``(B) is intended for use in clinical, laboratory, \n                or administrative workflow and related recordkeeping;\n                    ``(C)(i) is intended for use solely in the \n                transfer, aggregation, conversion (in accordance with a \n                present specification), storage, management, retrieval, \n                or transmission of data or information;\n                    ``(ii) utilizes a connectivity software platform, \n                electronic or electrical hardware, or a physical \n                communications infrastructure; and\n                    ``(iii) is not intended for use--\n                            ``(I) in active patient monitoring; or\n                            ``(II) in controlling or altering the \n                        functions or parameters of a device that is \n                        connected to such software;\n                    ``(D) is intended for use to organize and present \n                information for health or wellness education or for use \n                in maintaining a healthy lifestyle, including \n                medication adherence and health management tools;\n                    ``(E) is intended for use to analyze information to \n                provide general health information that does not \n                include patient-specific recommended options to \n                consider in the prevention, diagnosis, treatment, cure, \n                or mitigation of a particular disease or condition; or\n                    ``(F) is intended for use to analyze information to \n                provide patient-specific recommended options to \n                consider in the prevention, diagnosis, treatment, cure, \n                or mitigation of a particular disease or condition.\n    ``(2) The term `accessory' means a product that--\n            ``(A) is intended for use with one or more parent devices;\n            ``(B) is intended to support, supplement, or augment the \n        performance of one or more parent devices; and\n            ``(C) shall be classified by the Secretary--\n                    ``(i) according to its intended use; and\n                    ``(ii) independently of any classification of any \n                parent device with which it is used.''.\n\nSEC. 3. APPLICABILITY AND INAPPLICABILITY OF REGULATION.\n\n    Subchapter A of chapter V of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 351 et seq.) is amended by adding at the end the \nfollowing:\n\n``SEC. 524B. HEALTH SOFTWARE.\n\n    ``(a) Inapplicability of Regulation to Health Software.--Except as \nprovided in subsection (b), health software shall not be subject to \nregulation under this Act.\n    ``(b) Exception.--\n            ``(1) In general.--Subsection (a) shall not apply with \n        respect to a software product--\n                    ``(A) of a type described in subparagraph (F) of \n                section 201(ss)(1); and\n                    ``(B) that the Secretary determines poses a \n                significant risk to patient safety.\n            ``(2) Considerations.--In making a determination under \n        subparagraph (B) of paragraph (1) with respect to a product to \n        which such paragraph applies, the Secretary shall consider the \n        following:\n                    ``(A) The likelihood and severity of patient harm \n                if the product were to not perform as intended.\n                    ``(B) The extent to which the product is intended \n                to support the clinical judgment of a medical \n                professional.\n                    ``(C) Whether there is a reasonable opportunity for \n                a medical professional to review the basis of the \n                information or treatment recommendation provided by the \n                product.\n                    ``(D) The intended user and user environment, such \n                as whether a medical professional will use a software \n                product of a type described in subparagraph (F) of \n                section 201(ss)(1).\n    ``(c) Delegation.--The Secretary shall delegate primary \njurisdiction for regulating a software product determined under \nsubsection (b) to be subject to regulation under this Act to the center \nat the Food and Drug Administration charged with regulating devices. \n    ``(d) Regulation of Software.--\n            ``(1) In general.--The Secretary shall review existing \n        regulations and guidance regarding the regulation of software \n        under this Act. The Secretary may implement a new framework for \n        the regulation of software and shall, as appropriate, modify \n        such regulations and guidance or issue new regulations or \n        guidance.\n            ``(2) Issuance by order.--Notwithstanding subchapter II of \n        chapter 5 of title 5, United States Code, the Secretary may \n        modify or issue regulations for the regulation of software \n        under this Act by administrative order published in the Federal \n        Register following the publication of a proposed order.\n            ``(3) Areas under review.--The review of existing \n        regulations and guidance under paragraph (1) may include review \n        of the following areas:\n                    ``(A) Classification of software.\n                    ``(B) Standards for development of software.\n                    ``(C) Standards for validation and verification of \n                software.\n                    ``(D) Review of software.\n                    ``(E) Modifications to software.\n                    ``(F) Manufacturing of software.\n                    ``(G) Quality systems for software.\n                    ``(H) Labeling requirements for software.\n                    ``(I) Postmarketing requirements for reporting of \n                adverse events.\n            ``(4) Process for issuing proposed regulations, \n        administrative order, and guidance.--Not later than 18 months \n        after the date of enactment of this section, the Secretary \n        shall consult with external stakeholders (including patients, \n        industry, health care providers, academia, and government) to \n        gather input before issuing regulations, an administrative \n        order, and guidance under this subsection.\n    ``(e) Rule of Construction.--Nothing in this section shall be \nconstrued as providing the Secretary with the authority to regulate \nunder this Act any health software product of the type described in \nsubparagraph (F) of section 201(ss)(1) unless and until the Secretary \nhas made a determination described in subsection (b)(1)(B) with respect \nto such product.''.\n\nSEC. 4. EXCLUSION FROM DEFINITION OF DEVICE.\n\n    Section 201(h) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 321) is amended--\n            (1) in subparagraph (2), by striking ``or'' after ``or \n        other animals,'';\n            (2) in subparagraph (3), by striking ``and'' and inserting \n        ``or''; and\n            (3) by inserting after subparagraph (3) the following:\n            ``(4) is not health software (other than software \n        determined to be a risk to patient safety under section \n        524B(b)), and''."
}